Search PubMed⌕ Search

Biomedical subjects

Gideon Koren

Publications and source records attributed to Gideon Koren.

At least 253 records · Page 14Linked to original sources

Trends of medication errors in hospitalized children.

Medication errors are a major cause of morbidity and mortality among hospitalized children. Due to the small volumes of stock solution involved, even a large error may look as an unsuspiciously small dose. Strategies were implemented to reduce medication errors in a large tertiary pediatric hospital in Toronto. Starting in 1993, several initiatives were taken, including a new hospital computer system for medication ordering, a review process to remove hazardous drugs from wards where they are not needed immediately, and in the training of pediatric residents. The rates of reported medication errors were compared before and after these initiatives were taken. Compared to baseline, there was a steady and a statistically significant decrease in medication errors through the decade. Total errors (actual and potential) decreased for nurses and physicians by half and for pharmacists by 75%. Actual incidents decreased by half. Moderate and severe errors decreased by more than 70%. It was concluded that a combination of several initiatives to decrease system and human errors has resulted in more than a 50% reduction of medication errors reaching the pediatric patient.

Canada↗

Lidocaine-prilocaine cream versus tetracaine gel for procedural pain in children.

OBJECTIVE: To determine the relative efficacy of lidocaine-prilocaine and tetracaine for procedural pain in children. METHODS: Systematic review was performed (MEDLINE1990-June 2001) of all studies comparing the efficacy of these 2 modalities of pain relief in children undergoing painful cutaneous procedures. Search terms included lidocaine, prilocaine, tetracaine, and anesthesia. RESULTS: Eight studies compared lidocaine-prilocaine with tetracaine in children for 4 different procedures: intravenous cannulation, venipuncture, Port-a-Cath puncture, and laser therapy. When used as labeled (60 min for lidocaine-prilocaine, 30 min for tetracaine), the 2 modalities provided similar analgesic efficacy. When both anesthetics were applied for a similar duration of time (40 min, 60 min, 2 h), tetracaine provided superior anesthesia. Tetracaine was commonly associated with erythema, and lidocaine-prilocaine was associated with blanching of the skin. CONCLUSIONS: Lidocaine-prilocaine and tetracaine appear to be comparable for procedural pain relief when used as recommended. Tetracaine is more efficacious than lidocaine-prilocaine when both anesthetics are applied for the same amount of time.

Administration, Topical↗

Increased use of antidepressants in Canada: 1981-2000.

OBJECTIVE: To provide a descriptive analysis of Canadian utilization (prescriptions, cost, cost per prescription) of antidepressants (ATC-code: N06A). METHODS: IMS Canada provided prescription volumes and costs from 1981 to 2000. We analyzed time trends for antidepressants in general and 4 subclasses (tricyclic antidepressants [TCAs], selective serotonin-reuptake inhibitors [SSRIs], dual action antidepressants [DAAs], and monoamine oxidase inhibitors [MAOIs]). Costs were discounted using the consumer price index, adjusting for population growth using data from Statistics Canada. RESULTS: Between 1981 and 2000, total prescriptions increased from 3.2 to 14.5 million. Market share of TCAs (23.7%) and MAOIs (2.1%) remained constant, despite the introduction of the first SSRI, fluoxetine, in 1989. SSRI prescriptions increased to 6.7 million (market share 46.3%). DAA use increased gradually after 1994 to 3.5 million prescriptions (23.9% market share) in 2000. The number of prescriptions expanded (possibly due to SSRIs) by 238%, with an increased cost of 2.7 billion dollars. Total expenditures for antidepressants increased exponentially, from 31.4 million dollars in 1981 to 543.4 million dollars in 2000 (y = 4E - 130e(0.1556x) [R(2) = 0.99]). Cost per prescription increased linearly from 9.85 dollars in 1981 to 37.44 dollars in 2000 (y = 1.72x + 7.92 [R(2) = 0.96]). CONCLUSIONS: Utilization and costs of pharmacotherapy for depression have increased above the inflation rate and are expected to exceed 1.2 billion dollars (50 dollars per prescription) in 2005. Increased costs may be due to increased availability of new products with increased safety, efficacy, and acquisition cost; increased number of users; and increasing costs.

Antidepressive Agents↗

Variables associated with medication errors in pediatric emergency medicine.

OBJECTIVE: Medication errors are a common cause of iatrogenic morbidity and mortality. The incidence of medication errors in pediatric emergency departments (EDs) has not been described. The objective of this study was to describe the incidence and type of drug errors in a pediatric ED and determine factors associated with risk of errors. METHODS: A retrospective cohort study was conducted of the charts of 1532 children who were treated in the ED of a pediatric tertiary care hospital during 12 randomly selected days from the summer of 2000. Two pediatricians, blinded to other study variables, independently decided whether a medication error occurred and ranked it according to a severity score. Disagreement was resolved by consensus. RESULTS: Prescribing errors were identified in 10.1% of the charts. The following variables were associated in univariate analysis with an increased proportion of errors: patients seen between 4 AM and 8 AM (odds ratio [OR]: 2.45; 95% confidence interval [CI]: 1.10-5.50), patients with severe disease (OR: 2.53; 95% CI: 1.18-5.41), medication ordered by a trainee (OR: 1.48; 95% CI: 1.03-2.11), and patients seen during weekends (OR: 1.48; 95% CI: 1.04-2.11). Among trainees, there was a higher rate of errors at the beginning of the academic year (OR: 1.67; 95% CI: 1.06-2.64). Logistic regression revealed increased risk for errors when a medication was ordered by a trainee (OR: 1.64; 95% CI: 1.06-2.52) and in seriously ill patients (OR: 1.55; 95% CI: 1.06-2.26). CONCLUSIONS: In the pediatric ED, trainees are more likely to commit prescribing errors, and the most seriously ill patients are more likely to be subjected to prescribing errors.

Child↗

Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience.

OBJECTIVE: To review 10 years' experience in a tertiary care paediatric hospital of erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, to apply a recently described classification system for EM, SJS and TEN in children. DESIGN: Retrospective study of all children with a discharge diagnosis of EM, SJS or TEN over a 10-year period. SETTING: A university tertiary care paediatric hospital. PATIENTS: Sixty-one paediatric patients with a discharge diagnosis of EM, SJS or TEN. MAIN OUTCOME MEASURES: Epidemiology, laboratory features, causative factors, treatment methods, complications and mortality of EM, SJS and TEN in this group of patients. Comparison of correlation with aetiology of old and new classification systems in a paediatric population. RESULTS: Mucous membrane involvement was documented in 61% of patients. Ocular involvement was seen in 39%. Complications occurred in 21% cases, all of whom had SJS or TEN. Only one patient died as a result of their skin condition. Corticosteroids were used in 18% of cases; 95% of whom had a discharge diagnosis of SJS or TEN. The drugs most commonly identified as aetiological agents were sulphonamides and penicillins (26% each). The most frequently implicated infectious agent was herpes simplex virus (19.7%). Classification of study cases according to Bastuji-Garin et al. indicates a strong trend toward bullous EM cases being attributable to infection and SJS/TEN cases to drugs. There was no such clear trend with respect to aetiology when diagnosis was done without the classification system. CONCLUSION: EM, SJS and TEN rarely cause mortality but significant morbidity is seen. Infectious agents, particularly herpes simplex virus, and drugs, especially the sulphonamides and penicillins, are the most common aetiological agents. The classification system proposed by Bastuji-Garin et al. correlates better with aetiology than the practice that preceded it.

Child↗

Fetal pharmacotherapy.

Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and controversies in fetal pharmacotherapy. Unique pharmacokinetic features of pregnancy, the placenta and the fetus govern maternal-to-fetal drug transfer. Ethically, it is important that the mother and family are appropriately informed about the evidence in favour of specific fetal therapy, its risks and alternatives. Antenatal use of corticosteroids for lung maturation is an example of adequate methodology, leading to clear results. In contrast, the initial hopes in antenatal use of phenobarbital were based on less than optimal methodology. Folic acid for the prevention of neural tube defects is the first instance of fetal therapy that has led to the prevention of a major malformation. Serious infections, such as HIV, Group B streptococcus and toxoplasmosis highlight the need for controlled, randomised studies to prevent fetal infection. With scores of new modalities of fetal therapy likely to be introduced in the next few years, it will be important to adhere to the best possible methodology and execution, in order to address optimally the needs of the fetus.

Arrhythmias, Cardiac↗

Ethical issues in including pediatric cancer patients in drug development trials.

Since the biology, pharmacology and toxicology of pediatric cancer is so different from cancer in adults, it is impossible to extrapolate from adult cancer experience; however, conducting studies in children with cancer is ethically and clinically very complex. This is especially so in phase 1 trials, aimed at dose finding for new modalities, where the chances to cure the child who failed standard therapy are marginal to non-existent. Hence, the child may be exposed to risks and discomfort which may be unbalanced by potential benefits. This situation, which is difficult for consenting adults, is much more complex when a parent gives proxy consent. This review addresses the ethical and clinical framework of such studies in the most vulnerable of children.

Antineoplastic Agents↗

Drinking alcohol while breastfeeding. Will it harm my baby?

QUESTION: I recently delivered a healthy, full-term baby and am now breastfeeding exclusively. I abstained from drinking alcohol during my entire pregnancy and am wondering if drinking alcohol now would harm my nursing baby. ANSWER: Nursing mothers who choose to drink alcohol during the postpartum period should carefully plan a breastfeeding schedule by storing milk before drinking and waiting for complete elimination of alcohol from their breast milk after drinking. Motherisk has created an algorithm to estimate how long it takes to eliminate alcohol from breast milk.

Adult↗

Nausea and vomiting of pregnancy. Evidence-based treatment algorithm.

QUESTION: One of my patients suffers from a moderate-to-severe form of morning sickness. She responded only partially to doxylamine and pyridoxine (Dicletin), and I wish to try adding another medication. What should my priority be? ANSWER: An algorithm used by Motherisk to manage thousands of patients takes a hierarchical approach to this condition. This approach is evidence based with regard to fetal safety as well as efficacy.

Adult↗

Cystic fibrosis during pregnancy.

QUESTION: I have a 23-year-old patient with cystic fibrosis (CF) who recently married and has come to see me regarding preconception counseling and prospects of pregnancy. According to my sources, patients with CF can have successful pregnancies. How should I advise my patient? ANSWER: Cystic fibrosis in all degrees of severity is not a strict contraindication for pregnancy, especially if disease is mild; pregnancy by itself does not appear to adversely affect patients with CF. Pregnancy could proceed normally in women with normal lung function, but could adversely affect mild and moderate lung disease due to CF and should be avoided when patients have pulmonary hypertension or cor pulmonale, and when reduced lung function is predicted. Ideally, all pregnancies should be planned with prior counseling and be monitored by dedicated CF teams.

Adult↗

Use of warfarin during pregnancy.

QUESTION: One of my patients, who has been taking warfarin for some time for treatment and prophylaxis of deep vein thrombosis, became pregnant due to failed contraception. I am unsure how to counsel her. Is there evidence that warfarin use during pregnancy is associated with fetal risk? ANSWER: If possible, warfarin therapy should be avoided during pregnancy. If warfarin therapy is essential, it should be avoided at least during the first trimester (because of teratogenicity) and from about 2 to 4 weeks before delivery to reduce risk of hemorrhagic complications. Unfractionated heparin or low molecular weight heparin could be substituted when appropriate because these agents do not cross the placenta and are considered the anticoagulant drugs of choice during pregnancy.

Anticoagulants↗

Reliability of maternal reporting in identifying major congenital malformations.

We compared maternal reports of major congenital malformations with physicians' reports in a teratology counseling service. The reports of women followed during gestation were matched to those submitted by physicians caring for the infants. In 153/165 cases neither the mother nor the physician described major malformations. There were 12 cases where both mother and physician described similar major malformations. In several of them the mother used non-medical terms (eg "hole in the heart"). Maternal reports of major anomalies were in close agreement with physicians' reports. This lends credibility to research based on pregnancy follow-up with maternal reports that are corroborated by physicians' reports.

Abnormalities, Drug-Induced↗

Bacterial vaginosis during pregnancy. Should we screen for and treat it?

QUESTION: Some of my patients have been diagnosed with bacterial vaginousis (BV) during pregnancy; some have symptoms, others do not. Should I be treating them, and if so, with what? Also, should I be screening all my pregnant patients for BV? ANSWER: There appears to be no benefit to screening or treating pregnant women with an average risk of BV. It is not even clear that treating pregnant women at high risk of BV is beneficial. If you decide to treat, the drugs of choice are oral or intravaginal gel metronidazole or oral clindamycin. Both these drugs are safe to use throughout pregnancy.

Anti-Infective Agents↗

Taking ACE inhibitors during pregnancy. Is it safe?

QUESTION: A pregnant patient is taking enalapril for primary hypertension. How safe are angiotension-converting enzyme inhibitors (ACEI) during pregnancy? ANSWER: Evidence of whether ACEIs cause problems during the first trimester of pregnancy is reassuring. There is evidence that they cause severe renal and other problems during the second and third trimesters, however. These drugs should be avoided during pregnancy.

Abnormalities, Drug-Induced↗

Update on motherisk updates. Seven years of questions and answers.

QUESTION: Every month I read the Motherisk Updates in your journal and find them very helpful in counseling my patients on exposures during pregnancy and breastfeeding. I was wondering: what are the most common questions you receive from family physicians? ANSWER: Since the Motherisk Update began, we have received an increasing number of inquiries from family physicians across Canada. Most questions are about drug exposures. The three classes of drugs asked about most often are antidepressants, antiepileptics, and antihistamines.

Adult↗

Taking ginger for nausea and vomiting during pregnancy.

QUESTION: Many of my patients prefer to use natural or herbal medicines, such as ginger, before taking drugs to treat nausea and vomiting of pregnancy. Is there evidence that ginger is safe to use during pregnancy? Is it effective? ANSWER: Although ginger is used in many cultures to treat the symptoms of nausea and vomiting, no trials have established its safety for use during pregnancy. On the other hand, its efficacy has been documented in two randomized, blinded controlled trials.

Female↗

Eating fish during pregnancy. Risk of exposure to toxic levels of methylmercury.

QUESTION: One of my pregnant patients consumes four cans of tuna a week. She became very concerned when she read that tuna contains methylmercury, which is toxic to the fetal brain. How should I advise her? ANSWER: Fresh tuna might contain toxic levels of methylmercury, but levels are much lower in canned tuna. Reassure your patient that eating canned tuna will not harm her or her baby.

Adult↗